We delete unwanted bacteria.

We combine active microbial monitoring and phage-based precision antimicrobials to remove unwanted microbes.

Problem

[ 2050 anti bio thing ]

[ how many patients die / quality of life ] Infections are getting out of control. Antibiotics are a $40.7B market, but the increase in antibiotic resistance means that fewer classes of antibiotics will continue to be effective.

Goal & Opportunity

[Market size, lost revenue]

It's an unspoken understanding that hospitals are overrun with antibiotic resistant bacteria. Many hospitals lack the tools and capacity to properly monitor and control these strains. These strains end up in patients, causing additional surgeries, extended hospital stays, and other problems adding to $20B in additional healthcare costs. Many patients suffer from hospital-acquired infection.

Other than "adhering to best practices", there are few options, which will naturally lead to more antibiotic resistance.

Hospital-acquired infection control could lead to $25-30B in potential medical cost savings.
In-patient conditions are also a large opportunity, with septicemia (mostly nosocomial) costing $20B every year
Acute bacterial skin and skin structure infections, many caused by MRSA, are a $10B market
Other chronic infections that require constant microbial control include Hidradenitis suppurativa ($763M), UTI ($11M), IBD ($16.7B), and diabetic foot ulcers ($4.6B)

Applications

Hospitals & Clinics

We hypothesize that at least 10% of clinics and hospitals in the US that deal with antibiotic resistant strains and nosocomial infections are willing to pay $120,000 annually to monitor and develop phage-based precision antibiotics for prevention of antibiotic resistant nosocomial infection